Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih‐Wei Lin, Yang Lei, Teresa I. Ng, Preethi Krishnan, Sarah Kopecky‐Bromberg, Jens Kort, Federico J. Mensa – 20 November 2017 – Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options.

Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies

Tracey G. Simon, Lindsay Y. King, Dawn Q. Chong, Long H. Nguyen, Yanan Ma, Trang VoPham, Edward L. Giovannucci, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Raymond T. Chung, Xuehong Zhang, Andrew T. Chan – 20 November 2017 – Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk.

Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome

Vian Azzu, Joshua E. Elias, Adam Duckworth, Susan Davies, Rebecca Brais, Dinakantha S. Kumararatne, Alexander E. S. Gimson, William J. H. Griffiths – 20 November 2017 – Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency characterized by antibody deficiency, recurrent bacterial infections, and autoimmunity. Advanced chronic liver disease occurs in a subset of patients with CVID and manifests with various histological features, such as nodular regenerative hyperplasia, inflammation, fibrosis, and cholangiopathy.

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir – 20 November 2017 – Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument.

Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study

Cihan Yurdaydin, Onur Keskin, Çağdaş Kalkan, Fatih Karakaya, Aysun Çalişkan, Ersin Karatayli, Senem Karatayli, A. Mithat Bozdayi, Christopher Koh, Theo Heller, Ramazan Idilman, Jeffrey S. Glenn – 20 November 2017 – In a proof‐of‐concept (POC) study, the oral prenylation inhibitor, lonafarnib (LNF), decreased hepatitis D virus (HDV) RNA during 4 weeks of treatment. Here, we explored optimal LNF regimens.

Subscribe to